Guidance

Recommendations for research

Recommendations for research

The guideline committee has made the following recommendations for research.

Key recommendations for research

1 Coordination of care

What is the clinical and cost effectiveness of processes of care, including the role of multiple sclerosis (MS) specialist nurses and other healthcare professionals, to improve care coordination and health outcomes in adults with MS? [2022]

For a short explanation of why the committee made the recommendation for research, see the rationale section on coordination of care.

Full details of the evidence and the committee's discussion are in evidence review B: coordination of care.

2 Cognitive rehabilitation

For adults with MS, including people receiving palliative care, what is the clinical and cost effectiveness of non-pharmacological interventions for memory and cognitive problems? [2022]

For a short explanation of why the committee made the recommendation for research, see the rationale section on cognitive and memory problems.

Full details of the evidence and the committee's discussion are in evidence review H: non-pharmacological management of memory and cognitive problems.

3 Outcome measures for cognitive rehabilitation

What core outcome measures should be used for studies assessing memory and cognition in people with MS?

For a short explanation of why the committee made the recommendation for research, see the rationale section on cognitive and memory problems.

Full details of the evidence and the committee's discussion are in evidence review H: non-pharmacological management of memory and cognitive problems.

4 Continued relapses

Is intravenous methylprednisolone more clinically and cost effective than oral methylprednisolone in people with relapsing–remitting MS and people with secondary progressive MS with continued relapses? [2014]

5 Mobility

What is the optimal frequency, intensity and form of rehabilitation for mobility problems in people with MS? [2014]

Other recommendations for research

6 Spasticity

For adults with MS, including people receiving palliative care, what is the clinical and cost effectiveness of pharmacological interventions for generalised spasticity? [2022]

For a short explanation of why the committee made the recommendation for research, see the rationale section on spasticity.

Full details of the evidence and the committee's discussion are in evidence review F: pharmacological management of spasticity.

7 Vitamin D

Can vitamin D slow down the progression of disability in MS? [2014]

8 Information and support

What information, education and support do adults with clinically isolated syndrome and their families and carers find most useful? [2022]

For a short explanation of why the committee made the recommendation for research, see the rationale section on providing information and support.

Full details of the evidence and the committee's discussion are in evidence review A: information and support for patients, their families and carers.

9 Non-pharmacological management of fatigue

For adults with MS, including people receiving palliative care, what is the clinical and cost effectiveness of non-pharmacological interventions for fatigue? [2022]

For a short explanation of why the committee made the recommendation for research, see the rationale section on assessment and non-pharmacological management of fatigue.

Full details of the evidence and the committee's discussion are in evidence review C: non-pharmacological management of fatigue.

10 Pharmacological management of fatigue

For adults with MS, including people receiving palliative care, what is the clinical and cost effectiveness of pharmacological interventions for fatigue? [2022]

For a short explanation of why the committee made the recommendation for research, see the rationale section on pharmacological management of fatigue.

Full details of the evidence and the committee's discussion are in evidence review D: pharmacological management of fatigue.

11 Pain

For adults with MS, including people receiving palliative care, what is the clinical and cost effectiveness of non-pharmacological interventions for pain? [2022]

For a short explanation of why the committee made the recommendation for research, see the rationale section on pain.

Full details of the evidence and the committee's discussion are in evidence review G: non-pharmacological management of pain.

12 Ataxia and tremor

For adults with MS, what is the clinical and cost effectiveness of pharmacological interventions for ataxia and tremor? [2022]

For a short explanation of why the committee made the recommendation for research, see the rationale section on pharmacological management of ataxia and tremor.

Full details of the evidence and the committee's discussion are in evidence review I: pharmacological management of ataxia and tremor.